An open-label pilot study suggests that intravenous brexanolone may rapidly reduce psychotic, manic, and depressive symptoms in patients with postpartum psychosis, highlighting a potential new treatment option.
In this postmarketing surveillance data analysis, excessive sedation and loss of consciousness when receiving brexanolone occurred at lower rates than previously reported in clinical trials.
As of October 2023, the Neurosteroid Intervention for Menopausal and Perimenopausal Depression is no longer recruiting participants. Over the last few years we have heard a great deal about neurosteroids, also known as neuroactive steroids. [...]
The transition to menopause, or perimenopause, represents the passage from reproductive to non-reproductive life. During the perimenopause, women experience irregular menstrual cycles, which reflect the large fluctuations in ovarian hormone [...]
This review discusses the novel neurosteroid antidepressant brexanolone for the treatment of postpartum depression.
Neuroactive steroids, derivatives of allopregnanolone, may be effective for the treatment of premenstrual dysphoric disorder.
Over the last few years we have heard a great deal about neurosteroids, also known as neuroactive steroids. This class of compounds are steroid hormones produced in the brain and endocrine tissues which can [...]
Zuranolone or SAGE-217 is similar to brexanolone (marketed as Zulresso), the medication which was FDA-approved for the treatment of postpartum depression. Zuranolone is a neurosteroid, an analogue of allopregnanolone, which is a positive allosteric [...]
Sepranolone is a neuroseroid now in Phase II clinical trials for the treatment of premenstrual dysphoric disorder (PMDD). Â
While we have been talking about using brexanolone, marketed by Sage Therapeutics as Zulresso, for the treatment of postpartum depression, an oral version of this novel antidepressant - SAGE 217 or zuranolone - has [...]
